ALDX stock icon

Aldeyra Therapeutics
ALDX

$3.86
1.03%
 

About: Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Employees: 10

0
Funds holding %
of 6,689 funds
0
Analysts bullish %
of 4 analysts
0
News positive %
of 4 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

95% more call options, than puts

Call options by funds: $339K | Put options by funds: $174K

0.41% more ownership

Funds ownership: 59.7% [Q4 2023] → 60.11% (+0.41%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

6% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 33

4% less funds holding

Funds holding: 104 [Q4 2023] → 100 (-4) [Q1 2024]

6% less capital invested

Capital invested by funds: $124M [Q4 2023] → $116M (-$7.74M) [Q1 2024]

22% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 18

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$10
159%
upside
Avg. target
$10
159%
upside
High target
$10
159%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
Oppenheimer
Francois Brisebois
159%upside
$10
Outperform
Reiterated
6 May 2024
HC Wainwright & Co.
Matthew Caufield
159%upside
$10
Buy
Reiterated
6 May 2024
Oppenheimer
Francois Brisebois
159%upside
$10
Outperform
Upgraded
3 Apr 2024
HC Wainwright & Co.
Matthew Caufield
159%upside
$10
Buy
Reinstated
2 Apr 2024

Financial journalist opinion

Based on 4 articles about ALDX published over the past 30 days